6-Tert-butyl-2-propan-2-yl-1-benzothiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 6-Tert-butyl-2-propan-2-yl-1-benzothiophene
• 英文别名: 6-tert-butyl-2-propan-2-yl-1-benzothiophene
• 化学式: C₁₅H₂₀S
• 分子量: 232.4
• InChiKey: QEOXQBMMSFLEKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。
• Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：US10323023B2

  公开（公告）日：2019-06-18

  The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

  本发明涉及一种式（I）的Rho相关蛋白激酶抑制剂、一种包含其的药物组合物、其制备方法以及其用于预防或治疗由Rho相关蛋白激酶（ROCK）介导的疾病的用途。
• RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：US20190002442A1

  公开（公告）日：2019-01-03

  The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).
• METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS
  申请人：BEIJING TIDE PHARMACEUTICAL CO., LTD.

  公开号：US20220378743A1

  公开（公告）日：2022-12-01

  The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.